Figure 1
Percent of patients without relapse separated according to initial white blood cell count above (n = 17) and below 5000/l (n = 51) showing no significant difference (P = 0.56). Only hematological relapse was considered as an event.
We thank Dr Sanz and colleagues for their critical comments and would like to use the opportunity to contribute a few facts concerning the use of intensive chemotherapy in APL.
First, the importance of high dose ara-C in acute promyelocytic leukemia (APL) is underlined by several observations.
(1) First of all, the relapse rate at 2 or 3 years in our study is by far the lowest of all studies cited by Sanz et al (Table 1) . After combined double induction including high-dose ara-C and ATRA, there are no hematologic or clinical relapses until 3. years. 1 This is confirmed in the recent update of November 2000 with a longer follow-up (median 33 months) and a higher number of patients (n = 73). The rate of hematologic remission is 93%. Two hematologic relapses occurred, both after 3. years ( Figure 1 ). The treatment was feasible with an acceptable toxicity and a good compliance.
(2) After a median follow-up of about 12 to 15 months, in the Italian (GIMEMA) and Spanish (PETHEMA) trials not using intensive chemotherapy there were 17 hematologic relapses at 5-20 months among 229 remissions (GIMEMA) and five CNS or bone marrow relapses at 4-15 months among 109 remissions (PETHEMA), respectively. 2, 3 At the combined update of these two trials in 2000, there were 20 clinical relapses at 5-28 (median 16) months (GIMEMA) and at 9-17 (median 11) months (PETHEMA) among a total of 217 patients in remission who had completed all three consolidation courses and who were assigned to a particular subsequent treatment. 4 (3) Before the ATRA era double induction, consolidation and maintenance resulted in 66% remissions in the subset of 44 patients with APL. Relapse-free survival at 9 years was 67% in patients randomized to high-dose ara-C as part of induction and was 21% in those randomized to standard-dose ara-C (P = 0.02).
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(4) WBC count as a risk factor of relapse 3,4,6,7 has not been reproduced in the current trial of the AMLCG. 1 Even in patients with WBC count у5000/l, there was no hematologic relapse until 3. years ( Figure 1 ). Intensive chemotherapy including high dose ara-C may thus improve poor prognosis in APL as it does in other subtypes of AML. 8 (5) Since the kinetics of molecular remission was identified as one of two prognostic factors in APL in the British trials, 6 the rapid achievement of molecular remission reported by us 1 again suggests an improvement of poor prognosis. (6) The low relapse rate in the AMLCG study 1 is not explained by a comparatively high cumulative anthracycline dosage. Given the dose equivalents used by the EORTC 9 as daunorubicin (DNR) 50 mg = mitoxantrone 12 mg = idarubicin 10 mg, the cumulative DNR equivalent of 485 mg/m 2 given during induction and consolidation in the AMLCG study remains within the dose ranges of the other trials, 4, 6, 7 even if maintenance treatment is included in the calculation. 1 In contrast, the cumulative dosage of ara-C administered during induction and consolidation 1 exceeds the related maximum dosages in the British 6 and European 7 trials by approximately 100% and those in the Italian trial 4 by approximately 340%. The reduction in relapses thus appears essentially as an ara-C effect.
Second, there may be age-related differences in the response rates. They cannot explain, however, the major result of a 'particularly low relapse rate' in the AMLCG trial restricted to 16-60 years of age. Sanz and colleagues failed to demonstrate age as a risk factor of relapse in the combined Italian and Spanish data. 4 They even reported a 3 year remission duration of 100% in patients р15 years, 94/87% in patients 61-70 years, and 100% in patients Ͼ70 years of age.
If the possible influence of age on the remission rate is discussed, it should be emphasized that the inclusion of children may improve the results using suitable therapy. In a multicenter APL study of the pediatric German-Austrian-Swiss Cooperative Group, a remission rate of 95% was achieved in 22 children with ATRA and chemotherapy consisting of ara-C, daunorubicin or idarubicin, and etoposide (J Ritter, unpublished observation).
Third, in APL trials using up-front randomization thus providing intent-to-treat evaluation and representative results, the relapse risk was 20% and 36% at 4 years in two treatment arms with ATRA and chemotherapy in the British trials, 6 and the relapse rate was 6% and 16% with most of them at 1-3 years from two versions of ATRA and standard-dose chemotherapy restricted to patients with р5000/l WBC counts in the European APL-93 trial (Table 1) . 7 Fourth, an overview of APL study data available (Table 1) does not support the statement that '. . . comparable or even better results . . . have been extensively and consistently reported in other recent studies in which much less induction and consolidation chemotherapy were given'.
In conclusion, the data from alternative treatments in APL available so far justify and require further investigation by upfront randomized trials which also address the role of high-dose ara-C.
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